DPP4i treatment made simple.
TRAJENTA® (linagliptin) belongs to the class of oral anti-diabetic medications called DPP4 inhibitors (DPP4i).
DPP4i prolong the action of incretins (GLP-1 and GIP), and by working in a glucose dependent way they:1,2
Increase glucose dependent insulin secretion leading to increased glucose utilization by muscle and adipose tissue.
Increase glucose dependent glucagon suppression leading to decreased hepatic glucose release improving overall glucose control.
GLP-1: glucagon-like peptide-1; GIP: glucose-dependent insulinotropic polypeptide.
Thanks to this mode of action, DPP4i are generally associated with:3
TRAJENTA® is different from most of the other DPP4i because it is the only DPP4i primarily excreted via a non-renal route. That makes TRAJENTA® simple to use:4